Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

References

• Vose J, Armitage J, Weisenburger D; International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J clin oncol. 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, et al.; International Peripheral TCLP. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008;111:5496–5504.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J clin oncol. 2012;30:3093–3099.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al.; Group E-S. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–240.
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J clin oncol. 2013;31:1970–1976.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J clin oncol. 2017;35:4019–4026.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211–2217. Epub 2014/ 09/07.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J clin oncol. 1998;16:3803–3809.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group. Blood. 2010;116:3418–3425.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101:e27–e29.
   PubMed Web of Science ®Google Scholar
• Peng YL, Huang HQ, Lin XB, et al. Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen. Ai Zheng. 2004;23:943–946.
   PubMedGoogle Scholar
• Roswarski J, Roschewski M, Melani C, et al. Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Leuk Lymphoma. 2019;60:2062–2066.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Zelenetz AD, Gordon LI, et al. NCCN guidelines insights: non-hodgkin’s lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016;14:1067–1079.
   PubMed Web of Science ®Google Scholar
• Ellin F, Landstrom J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 2014;124:1570–1577.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al.; Network TcP. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the international T cell project network. Br J Haematol. 2018;181:760–769. Epub 2018/ 04/20.
   PubMed Web of Science ®Google Scholar
• Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes for relapsed and refractory peripheral t-cell lymphoma patients after front-line therapy from the COMPLETE registry. Acta Haematol. 2020;143:40–50. Epub 2019/ 07/18.
   PubMed Web of Science ®Google Scholar
• Park SI, Horwitz SM, Foss FM, et al.; Investigators C. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125:1507–1517. Epub 2019/ 01/30.
   PubMed Web of Science ®Google Scholar
• Jia B, Hu S, Yang J, et al. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology. 2016;21:536–541.
   PubMed Web of Science ®Google Scholar
• Yao YY, Tang Y, Zhu Q, et al. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma. 2013;54:1194–1200.
   PubMed Web of Science ®Google Scholar
• Mehta N, Maragulia JC, Moskowitz A, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13:664–670.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J clin oncol. 2011;29:1182–1189.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J clin oncol. 2012;30:631–636.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J clin oncol. 2015;33:2492–2499.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J clin oncol. 2012;30:2190–2196.
   PubMed Web of Science ®Google Scholar
• Malik SM, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. food and drug administration drug approval summary. Clin Cancer Res. 2010;16:4921–4927.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Moccio DM, et al.; New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol. 1984;12:18–25.
   PubMed Web of Science ®Google Scholar
• Wang ES, O’Connor O, She Y, et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003;44:1027–1035.
   PubMed Web of Science ®Google Scholar
• Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opin Drug Metab Toxicol. 2011;7:1141–1152.
   PubMed Web of Science ®Google Scholar
• Marchi E, Mangone M, Zullo K, et al. Pralatrexate pharmacology and clinical development. Clin Cancer Res. 2013;19:6657–6661.
   PubMed Web of Science ®Google Scholar
• Krug LM, Ng KK, Kris MG, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6:3493–3498.
   PubMed Web of Science ®Google Scholar
• Mould DR, Sweeney K, Duffull SB, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-hodgkin’s or hodgkin’s lymphoma. Clin Pharmacol Ther. 2009;86:190–196.
   PubMed Web of Science ®Google Scholar
• Merdin A, Iskender D, Ulu BU, et al. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: case report of a patient followed-up over 3 years under pralatrexate treatment. Medicine (Baltimore). 2019;98:e16482.
   PubMed Web of Science ®Google Scholar
• Hong X, Song Y, Huang H, et al. Pralatrexate in chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study. Target Oncol. 2019;14:149–158.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Nagai H, Maeda Y, et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017;108:2061–2068.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Marchi E, Volinn W, et al. Strategy for assessing new drug value in orphan diseases: an international case match control analysis of the PROPEL study. JNCI cancer spect. 2018;2:pky038.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Ozcan M, Jacobsen ED, et al.; Lumiere Study I. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J clin oncol. 2019;37:613–623.
   PubMed Web of Science ®Google Scholar
• Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172:535–544.
   PubMed Web of Science ®Google Scholar
• Toner LE, Vrhovac R, Smith EA, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-hodgkin’s lymphoma. Clin Cancer Res. 2006;12:924–932.
   PubMed Web of Science ®Google Scholar
• Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131:397–407.
   PubMed Web of Science ®Google Scholar
• Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21:2096–2106.
   PubMed Web of Science ®Google Scholar
• Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010;16:3648–3658.
   PubMed Web of Science ®Google Scholar
• Foss FM, Parker TL, Girardi M, et al. Clinical activity of pralatrexate in patients with cutaneous T-cell lymphoma treated with varying doses of pralatrexate. Clin Lymphoma Myeloma Leuk. 2018;18:e445–e7.
   PubMed Web of Science ®Google Scholar
• Foss FM, Parker TL, Girardi M, et al. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. Leuk Lymphoma. 2019;60:2927–2930.
   PubMed Web of Science ®Google Scholar
• Haddad P. Efficacy of shrt oral leucovorin rescue in managing recurrent pralatrexate induced mcuositis despite dose reduction. Blood. 2011;118:4745.
   Google Scholar
• Koch E, Story SK, Geskin LJ. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma. 2013;54:2448–2451.
   PubMed Web of Science ®Google Scholar
• Marneros AG, Grossman ME, Silvers DN, et al. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. Blood. 2009;113:6338–6341.
   PubMed Web of Science ®Google Scholar
• de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–4963.
   PubMed Web of Science ®Google Scholar
• Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983–2986.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095–3100.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119:4115–4122.
   PubMed Web of Science ®Google Scholar